FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Federal Register

Comments Sought on Premarket Safety Workshop

Federal Register notice: FDA requests comments on the topics discussed at its 9/14 public workshop entitled Advancing Premarket Safety Analytics Works...

Human Drugs

MIDD Paired Meeting Updates

FDA posts PDUFA 7 updates to the model-informed drug development paired meeting program.

latest-news-card-1
Human Drugs

GSK Stops UTI Trials and Opts for NDA

GSK stops enrollment early due to positive results two Phase 3 trials evaluating gepotidacin, an investigational drug for uncomplicated urinary tract ...

latest-news-card-1
Human Drugs

FDA, Others Launch Global Substances System

FDA says it is working with the National Institutes of Health and the European Medicines Agency on a global substance registration system.

latest-news-card-1
Federal Register

Draft Guide on OTC Monograph Fees

Federal Register notice: FDA makes available a draft guidance entitled Assessing User Fees Under the Over-the-Counter Monograph Drug User Fee Program....

latest-news-card-1
Federal Register

Guidance on Pharmaceutical Carcinogenicity Testing

Federal Register notice: FDA makes available a final guidance entitled S1B(R1) Addendum to S1B Testing for Carcinogenicity of Pharmaceuticals.

latest-news-card-1
Human Drugs

Oncology Drug Cross Labeling Guidance

FDA publishes a guidance on cross-labeling of oncology drugs used in combination regimens.

latest-news-card-1
Medical Devices

Teleflex Filter Recall is Class 1

FDA says the Teleflex recall of 60,000 Iso-Gard Filter S units is Class 1.

latest-news-card-1
Human Drugs

Temporary Clozapine REMS Enforcement Discretion

FDA announces new enforcement discretion and reiterates previous enforcement discretion relating to issues with the clozapine REMS program.

latest-news-card-1
Federal Register

Guide on Expanded Access for Investigational Drugs

Federal Register notice: FDA makes available a revised draft guidance entitled Expanded Access to Investigational Drugs for Treatment Use: Questions a...